Pay in 4 interest-free payments of $5.73 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
Neuropharmacology 93:134145
2 The findings from the OASIS 4 trial, published in the New England Journal of Medicine in September 2025, led the FDA to approve the Wegovy pill in December 2025, making it the first oral GLP-1 medication approved specifically for weight loss
Phase 2 trial (NEJM 2023) randomized 338 adults with obesity to retatrutide doses from 1 mg to 12 mg/week
Neurotrauma 19 , 815828 (2002)
There are also warnings about thyroid Ccell tumors in animal studies for some drugs, and clinician screening is important
US$ 27.72
US$ 21.16
US$ 21.46
US$ 24.66
